|
| Status |
Public on May 14, 2022 |
| Title |
Molecular subtyping of “double negative” MIBC |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Identifying patients that benefit from cisplatin-based adjuvant chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC). The purpose of this study is to correlate “luminal” and “basal” type protein expression with histological subtypes, to investigate the prognostic impact on survival after adjuvant chemotherapy and to define molecular subtypes of “double negative” patients (i.e. without expression of CK5/6 or GATA3).
|
| |
|
| Overall design |
10 IHC-double negative cases were analyzed with the HTG transcriptome panel with 19398 mRNA targets. Molecular consensus classification was determined according to Kamoun et al. (Euro Urol, 2019)
|
| |
|
| Contributor(s) |
Döring C, Koll FJ |
| Citation(s) |
35783619 |
| |
| Submission date |
Mar 14, 2022 |
| Last update date |
Jul 07, 2022 |
| Contact name |
Florestan Johannes Koll |
| E-mail(s) |
florestanjohannes.koll@kgu.de
|
| Organization name |
University Hospital Frankfurt, Goethe University
|
| Department |
Department of Urology
|
| Street address |
Theodor-Stern-Kai 7
|
| City |
Frankfurt |
| ZIP/Postal code |
60590 |
| Country |
Germany |
| |
|
| Platforms (1) |
|
| Samples (10)
|
|
| Relations |
| BioProject |
PRJNA816119 |
Less...
More...